Sword Health: The Clear Successor to the Digital MSK Throne

Nelson Advisors
46 minutes ago
10 min read

The Healthtech IPO Rebound and Valuation Reset

The public equity landscape for healthcare technology underwent a major structural re-engineering in mid-2025, breaking a multi-year listing drought that had frozen the exit pipeline since the market correction of late 2021. This revival was led by a cohort of highly scaled, operationally disciplined enterprise platforms that demonstrated a decisive shift away from speculative models toward sustainable margins and validated clinical evidence. This transition was defined by a brief opening of the public window that allowed five pioneering healthtech companies, Hinge Health, Omada Health, HeartFlow, Carlsmed, and Profusa, to complete their listings.

Hinge Health priced its initial public offering on May 21st, 2025, listing on the New York Stock Exchange under the ticker symbol HNGE. Pricing at the top of its expected range of $28 to $32 per share, the company raised $437 Million at an implied valuation of $2.6 Billion. Lead underwriters on the transaction included Morgan Stanley, Barclays, and BofA Securities, signaling robust institutional support for the offering.

Shortly thereafter, on June 6th, 2025, chronic care management platform Omada Health completed its IPO, listing on the NASDAQ under the ticker symbol OMDA. Underwritten by Morgan Stanley, Goldman Sachs, and J.P. Morgan, the transaction raised $150 Million at an implied valuation of approximately $1.1 Billion.

These listings established a clear valuation benchmark for the digital health sector. Speculative pandemic-era multiples of 15x to 20x forward revenues were permanently replaced. In the post-2025 market, core digital health companies are valued within a normalised range of 4x to 6x revenue.

Premium platforms presenting proprietary artificial intelligence, deep clinical workflow integration, and validated data moats can command multiples of 6x to 8x+. Conversely, sub-scale or unprofitable companies without clinical evidence are compressed to multiples of 3x to 4x revenue.

The financial graduation benchmarks of the mid-2025 IPO class are detailed below:

Metric	Hinge Health (NYSE: HNGE)	Omada Health (NASDAQ: OMDA)
IPO Pricing Date	May 21st, 2025	June 5th, 2025 (Traded June 6)
IPO Share Price	$32.00	$19.00
Raised Capital	$437 Million	$150 Million
Implied Valuation at IPO	$2.6 Billion	$1.1 Billion
Adjusted Gross Margin	83% – 85%	65% – 70% (Est.)
EV / Revenue Multiple	5.7x	2.5x
Annualized Growth Rate	72%	65%
Free Cash Flow Margin	26%	-1%
Rule of 40 Score	98%	64%

While the public markets opened briefly in mid-2025, early 2026 witnessed a renewed freeze for the digital health sector. Non-digital healthcare segments continued to thrive, as evidenced by biotechnology companies raising over $1 Billion in a single week and emergency transport provider GMR Solutions raising $479 Million.

The core digital health window remained closed during the first half of 2026, creating an exit backlog paradox: dozens of late-stage digital health platforms that raised massive venture rounds at peak valuations are now forced to wait for public market stability, as few strategic buyers possess the balance sheet capacity to acquire them at their current private valuations.

Sword Health: The Clear Successor to the Digital MSK Throne

Within the specialised digital musculoskeletal care sector, Sword Health stands as the definitive candidate for the next initial public offering. Founded in 2014 by Virgílio Bento and André Eiras dos Santos, the company has sequentially scaled its capital structure to construct a massive competitive moat. Sword's private funding history reflects a textbook progression of late-stage institutional capitalisation, culminating in a series of rounds that expanded its valuation from $2 Billion in late 2021 to $3 Billion in mid-2024 and eventually to $4 Billion following a $40 Million venture round led by General Catalyst in June 2025.

By January 2026, private market transactions and junior funding rounds valued the company at approximately $4.15 Billion, indicating continued valuation step-ups despite a highly volatile venture capital environment.

Unlike many of its late-stage peers, Sword Health has successfully transitioned into a market consolidator, approaching consistent profitability with an annualised revenue run rate of approximately $240 Million. This transition is underscored by the company’s aggressive mergers and acquisitions strategy. The company has selectively acquired key technologies to broaden its clinical footprint, including the acquisition of the electronic platform Preventure in early 2023, the workers' compensation solution Surgery Hero in January 2025.

This acquisition sequence has expanded Sword Health’s access to approximately 100 Million covered lives across the United States and Europe, transforming it from a musculoskeletal point solution into a comprehensive platform spanning physical therapy, pelvic health, mental health and cardio-metabolic care.

A watershed moment for the digital MSK sector occurred on January 28th, 2026, when Sword Health announced the acquisition of Munich-based competitor Kaia Health for $285 Million. This transaction directly resolved the industry's longest standing technological debate: the clinical efficacy of hardware sensors versus software-only computer vision.

By acquiring Kaia, Sword adopted a hybrid care strategy designed to segment the market based on clinical acuity and delivery costs:

High-Acuity Care and Post-Surgical Rehabilitation

Patients recovering from invasive orthopaedic surgeries or suffering from severe chronic pain continue to utilise Sword's clinical-grade "Digital Therapist" system, which leverages FDA-listed wearable Inertial Measurement Units (IMUs) to track patient movement with clinical-grade precision.

Low-Acuity Care and Injury Prevention

For preventative programs or employees with mild discomfort, Sword deploys Kaia's "Motion Coach" technology, which utilises the camera on a patient's smartphone to track skeletal alignment points without external hardware. This eliminates the shipping logistics, inventory management costs and product specific Cost of Goods Sold (COGS) associated with physical kits, enabling Sword to offer a highly scalable, low-cost customer acquisition funnel.

This strategic integration extends to Sword's data engine and generative AI therapy agent, Phoenix, which was launched in June 2024. By combining the world's largest dataset of sensor-based movement data (Sword) with the largest dataset of vision-based movement data (Kaia), Sword’s AI models can now correlate visual cues, such as a user's facial grimace of pain, with bio-mechanical trembling detected in the sensor readings. This unified data engine provides predictive modelling to forecast surgical needs, significantly enhancing the platform's clinical and economic value proposition.

Competitive Dynamics and Public-Private Market Realities

The competitive landscape of the digital MSK market is characterised by a fierce rivalry between Sword Health and the newly public Hinge Health. While Hinge Health remains the revenue and market-share leader, projecting 2026 revenue to hit between $732 Million and $742 Million (with some analyst projections scaling up to $801 Million following strong Q1 performance), Sword has leveraged its clinical-grade model to position itself as a premium, highly effective alternative.

Sword’s clinical model is built upon remote supervision by licensed physical therapists (remote Doctors of Physical Therapy), and the company actively markets against Hinge's use of non-clinical health coaches, claiming that clinical rigour leads to superior outcomes and validated claims reduction.

To counter Hinge’s extensive distribution network, which covers 25 Million contracted lives and partnerships with all major national health plans, Sword has pioneered a 100% risk-based pricing model. Under this arrangement, Sword only charges employers and insurers if the patient achieves defined, documented clinical outcomes. This risk-sharing strategy has proven highly attractive to self-insured employers suffering from "point-solution fatigue" and surging healthcare expenditures.

The operational and financial standing of the leading digital MSK contenders is compared below:

Metric	Sword Health (Combined Entity)	Hinge Health (NYSE: HNGE)	Metric
Market Valuation	$4.0 Billion – $4.15 Billion (Est.)	$3.5 Billion – $4.5 Billion (Public Cap)	Market Valuation
Covered Lives	~100 Million (Enterprise Access)	~25 Million +	Covered Lives
Clinical ROI Claim	3.2:1 (Validated claims savings)	2.4:1 (Historical claims)	Clinical ROI Claim
Clinical Staff Model	Licensed Physical Therapists (DPTs)	Physical Therapists + Health Coaches	Clinical Staff Model
Hardware Strategy	IMU Sensors (High-Acuity) + Camera (Low-Acuity)	IMU Wearables + Enso Pain Management Device	Hardware Strategy
Regulatory Standing	DiGA Directory Listing (Germany)	FDA Clearance (Enso Device)	Regulatory Standing

While Sword Health boasts superior capital efficiency and a diversified clinical portfolio, it faces significant valuation hurdles relative to public comparables. In early 2026, the public market priced digital health companies at a standard EV/Revenue multiple of 4x to 6x, with premium platforms commanding 6x to 8x+. Sword's private valuation of $4.15 Billion against a $240 Million revenue run rate implies an EV/Revenue multiple of approximately 17.3x. This valuation discrepancy represents a substantial private-to-public pricing gap.

For Sword to successfully execute an IPO without facing a down-round correction, it must aggressively expand its revenue through the integration of Headspace and Kaia, driving down customer acquisition costs (CAC) and converting its 100 Million accessible lives into active, high-margin revenue streams.

The Landscape of Adjoining Competitors and Specialised Contenders

Beyond the dominant duopoly of Hinge and Sword, the digital musculoskeletal sector has produced a diverse cohort of mid-stage private companies and specialised platforms. These platforms are aggressively expanding within niche markets, positioning themselves as alternative targets for strategic acquisition or future public offerings:

Vori Health

Representing the nation's pioneering physician-led solution for virtual musculoskeletal care, Vori Health secured an oversubscribed $53 Million Series B funding round in March 2025. Led by New Enterprise Associates (NEA) with continued support from AlleyCorp, Intermountain Ventures, and Echo Health Ventures, the platform has achieved an 800% revenue increase over an 18-month period.

Vori Health’s clinical model integrates board-certified specialty medical physicians, physical therapists, registered dietitians, and health coaches to deliver a cohesive, collaborative care pathway. By integrating diagnostic specialty physicians directly into the virtual care team, Vori can eliminate unnecessary procedures and coordinate care with a validated 4:1 claims-based ROI. Private market models estimate Vori Health's valuation at approximately $177.9 Million, establishing it as a highly attractive mid-market player.

Bardavon Health Innovations

Headquartered in Overland Park, Kansas, Bardavon focuses heavily on the workers' compensation and risk management sectors. The company deploys a cloud-based clinical intelligence and analytics platform designed to synchronize and audit physical therapy practices for injured workers, thereby reducing workers' compensation medical and indemnity costs.

Bardavon has raised a total of $123 Million across seven funding rounds, backed by prominent growth investors including Matrix Capital Management and WestCap. The company has steadily expanded its executive leadership, appointing Jen Henry, DPT, MPH, to lead clinical operations and services in January 2025, and launching Recovery+ to set a new standard for workers' compensation rehabilitation.

Secondary Markets as a Strategic Buffer to IPO Horizons

One of the most consequential developments in the late-stage healthtech ecosystem is the rapid maturation of the secondary private markets. Platforms such as Nasdaq Private Market, Forge Global and EquityZen have evolved into highly structured financial environments, offering alternative liquidity pathways that directly influence the timing of initial public offerings. According to data from Lexington Partners, private secondary transactions reached a historic high, driven by an acute structural need for liquidity in the face of a stagnant public IPO window. Institutional interest has surged, with total capital in the secondary sector reaching $687 Billion and major financial institutions like Goldman Sachs, Morgan Stanley and Charles Schwab actively acquiring secondary investment firms to capture this volume.

For late-stage digital health platforms like Sword Health, the availability of deep secondary market liquidity represents a highly effective operational buffer. Sword's CEO, Virgílio Bento, has spent considerable time studying the public markets, ultimately identifying ten operational and strategic reasons to delay an initial public offering.

Bento has argued that highly resilient companies, such as Ikea and Lego, can maintain massive global growth while remaining entirely private, dismissing the notion that an IPO is a mandatory milestone for brand visibility or capital accumulation. Pointing to Databricks' ability to secure private liquidity, Sword has instead leveraged structured secondary tender offers and ESOP buybacks to manage its capitalisation table.

This secondary playbook delivers several critical operational benefits for a late-stage market consolidator:

Insulation from Public Market Volatility: Public healthtech listings have suffered from extreme post-IPO volatility. Remaining private shields Sword from short-term quarterly market optics, allowing the management team to focus on long-term clinical integrations.
Mitigation of Integration Scrutiny: Integrating Kaia Health's software clients and migrating them to Sword's sensor platform in the United States represents a high-risk operational maneuver. By executing this integration privately, Sword avoids the public fallout of potential client attrition or margin compression.
Execution of ESOP Liquidity: Rather than forcing employees and early backers to wait a decade or more for an IPO, Sword can periodically organize private tender offers, such as its $100 million and $54 million secondary rounds, to provide liquidity and refresh its equity structure.

This private liquidity strategy is not unique to Sword Health. For example, the healthcare data intelligence cloud platform Innovaccer completed a $75 Million secondary ESOP buyback in January 2026 to provide liquidity to early employees and signal structured financial preparation for an IPO, demonstrating how late-stage platforms utilise the secondary market to manage their capital runways before eventually stepping into the public eye.

Conclusions and Actionable Outlook

The digital musculoskeletal care sector has reached an operational inflection point. The mid-2025 public listings of Hinge Health and Omada Health proved that public markets are highly receptive to scaled, operationally disciplined digital health platforms with validated clinical evidence and strong unit economics.

However, the selective stagnation of the public window throughout 2026 has forced late-stage private companies to carefully evaluate their public timelines.

Sword Health represents the definitive next digital MSK company prepared for an initial public offering. Boasting an annualised revenue run rate of approximately $240 Million, positive cash flows, and a comprehensive platform spanning MSK, pelvic health, mental health, and cardiometabolic care, the company has successfully constructed a trans-continental clinical empire. Yet, the execution of this IPO is mediated by a highly deliberate private-equity strategy.

Sword's management team has guided the market toward a potential 2028 listing timeline, prioritising the integration of Kaia Health and Headspace, the upselling of its US enterprise accounts, and the expansion of its Phoenix AI therapy models.

While market observers note that secondary liquidity pressures or strong public performances from Hinge Health could accelerate Sword’s timeline to late 2027, the private markets currently offer a highly liquid, non-regulatory alternative to public listing.

For private equity investors, corporate strategists and public market specialists, the digital MSK landscape through 2027 will not be defined by a rushed public listing, but by the private optimisation of Sword Health's consolidated clinical engine as it prepares to challenge Hinge Health on the public stage.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech